Venbio Partners
$519M 13F equity value
8 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Venbio Partners covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PHVS | PHARVARIS N V | 4,643,430 | $161M | 30.9% |
| PBLS | PARABILIS MEDICINES INC | 5,266,697 | $144M | 27.8% |
| ALMS | ALUMIS INC | 4,528,408 | $127M | 24.5% |
| ACHV | ACHIEVE LIFE SCIENCE INC | 5,914,720 | $39M | 7.4% |
| ALXO | ALX ONCOLOGY HLDGS INC | 12,884,638 | $27M | 5.1% |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | 472,194 | $17M | 3.3% |
| LYEL | LYELL IMMUNOPHARMA INC | 337,697 | $5M | 0.9% |
| ARTV | ARTIVA BIOTHERAPEUTICS INC |
Track Venbio Partners's 13F portfolio: $519M in reported holdings, 8 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}